<I>TheStreet</I> Readers Make Perfect Predictions in Drug-Approval Contest

BOSTON ( TheStreet) --Congratulations to the 11 perfect winners of TheStreet's Summer FDA Drug Approval Contest.

"Perfect" because each of the winning contestants went 5-0 in predicting correctly the outcome of the following FDA-related events:

1. Onyx Pharmaceuticals ( ONXX): FDA advisory panel for the cancer drug carfilzomib on June 20.

2. Arena Pharmaceuticals ( ARNA): FDA approval decision for the weight-loss drug lorcaserin on June 27.

3. Vivus ( VVUS): FDA approval decision for the weight-loss drug Qnexa on July 20.

4. Amarin ( AMRN): FDA approval decision for the prescription fish-oil pill AMR101 on July 26.

5. Onyx: FDA approval decision for carfilzomib on July 27.

The 11 winners emerged from a record crowd of 134 entries. You can read more about the overall predictions from the contest here.

As you read your name, please take a bow and accept my hearty congratulations:
The Boss
MarywasavirginLOL
BobH
Seth Lewis
Ken Lauder
Eric
i1Again
Max
Tricia Dineen
Isitabubble

That's only 10 names. Who was winner No. 11?

Me! Yes, it's true, I actually won my own contest -- without cheating.

Thanks again for participating.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes